挽救性放疗后生化失败对前列腺癌特异性死亡率的影响:年龄与生化失败时间的竞争
这项回顾性多机构研究纳入547例淋巴结阴性前列腺癌患者,分析挽救性放疗后生化复发的时间分布及其对远处转移和前列腺癌特异性死亡率的影响。结果显示,放疗后18个月内出现生化复发与远处转移、前列腺癌特异性死亡和总死亡风险显著升高相关,并提供了基于年龄和生化复发时间的预测模型。
要点
- 挽救性放疗后10年生化复发累积发生率为60%。
- 生化复发≤18个月与远处转移风险升高相关(HR 7.44)。
- 生化复发≤18个月与前列腺癌特异性死亡风险升高相关(HR 12.3)。
核心结论
- 相当大比例男性在挽救性放疗后早期出现生化复发,且远处转移和前列腺癌特异性死亡风险更高。
- 需要新型预测生物标志物来识别微转移疾病患者,以避免可能无效的局部治疗或允许强化全身治疗。
研究设计与样本
- 回顾性多机构研究,纳入1985年至2013年接受挽救性放疗的547例连续淋巴结阴性前列腺癌男性。
- 挽救性放疗后中位随访时间为8.4年。
- 所有患者接受三维适形或调强放疗。
- 生化复发定义为前列腺特异性抗原(PSA)较最低值升高≥0.2ng/ml,且后续序列值相等或更高。
主要发现
- 挽救性放疗后10年生化复发累积发生率为60%。
- 274例发生生化复发的男性中,149例(54%)在挽救性放疗后18个月内出现生化复发。
- 挽救性放疗后生化复发≤18个月与远处转移风险升高相关(HR 7.44,95%CI 4.91-11.3;p<0.001)。
- 挽救性放疗后生化复发≤18个月与前列腺癌特异性死亡风险升高相关(HR 12.3,95%CI 5.95-25.2;p<0.001)。
- 挽救性放疗后生化复发≤18个月与总死亡风险升高相关(HR 2.85,95%CI 1.94-4.17;p<0.001)。
关键数值与推荐
- 生化复发定义为PSA较最低值升高≥0.2ng/ml,且后续序列值相等或更高。
- 提供了利用年龄和生化复发时间估算远处转移和前列腺癌特异性死亡累积发生率的模型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 分析的回顾性性质限制了研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease progression following salvage radiotherapy (SRT) for prostate cancer (PC) is common, and the time to biochemical recurrence (BCR) is heterogeneous. OBJECTIVE: To describe the temporal distribution and clinical impact of BCR following SRT and model outcomes using patient age and time to BCR from SRT. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multi-institutional study included 547 consecutive men with lymph node-negative PC receiving SRT from 1985 to 2013. The median follow-up after SRT was 8.4 yr. Intervention All men received SRT with three-dimensional or intensity-modulated RT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: BCR was defined as a rise in prostate-specific antigen (PSA) ≥0.2ng/ml above the PSA nadir followed by a sequentially equal or higher value. Additional outcomes included distant metastasis (DM), PC-specific mortality (PCSM), and overall mortality (OM). Cox proportional hazards models, a landmark analysis, and comparison of c-indices were used. Cumulative incidence curves were estimated from a Fine and Gray regression model. RESULTS AND LIMITATIONS: The estimated 10-yr cumulative incidence of BCR was 60%. Of the 274 men experiencing BCR, 149 (54%) had BCR within 18 mo of SRT. BCR ≤18 mo after SRT was associated with a higher risk of DM (hazard ratio [HR] 7.44, 95% confidence interval [CI] 4.91-11.3; p<0.001), PCSM (HR 12.3, 95% CI 5.95-25.2; p<0.001), and OM (HR 2.85, 95% CI 1.94-4.17; p<0.001). We provide a model to estimate the cumulative incidence of DM and PCSM using age and time to BCR. The retrospective nature of our analysis limits our findings. CONCLUSIONS: A strikingly large proportion of men experience early BCR following SRT and are at higher risk of DM and PCSM. Novel predictive biomarkers are needed to identify men harboring micrometastatic disease to avoid potentially futile local therapies or allow for intensification of systemic therapies. PATIENT SUMMARY: Many men will develop biochemical recurrence of prostate cancer after salvage radiotherapy. Men with biochemical recurrence within 18 mo of salvage radiotherapy constitute a cohort at higher risk of distant metastasis and prostate cancer-specific mortality.
引用
- Jackson WC, Suresh K, Tumati V, et al. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. Eur Urol Oncol. 2018. PMID: 31100248. doi:10.1016/j.euo.2018.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。